Plasmonics-active metal nanostar compositions and methods of use

Patent metadata

Field	Value
Publication number	US-9789154-B1
Application number	US-201313888226-A
Country	US
Kind code	B1
Filing date	May 6, 2013
Priority date	May 4, 2012
Publication date	Oct 17, 2017
Grant date	Oct 17, 2017

Abstract

Plasmonics-active metal nanostars are provided that can be used for treating and detecting cells in a subject. The modes of treatment include a photo-activated drug, which is activated by the photo-response of the nanostar to electromagnetic stimulation; a thermally-activated drug, which is activated by a thermal response of the nanostar to electromagnetic stimulation; and the thermal response of the nanostar itself to electromagnetic stimulation, which may directly or indirectly cause the death of an undesirable cell. Uptake of nanostars by undesirable cells may also aid in detection, by enhancing contrast or otherwise transforming electromagnetic stimulation during imaging.

First claim

What is claimed is:

1. A method for preparing plasmonics-active gold nanostars, the method comprising:
adding citrate stabilized gold seeds to a solution of tetrachloroauric acid (HAuCl 4 ) under acidic conditions; and
mixing a silver salt compound and a weak reducing agent simultaneously into the HAuCl 4 /gold seed solution under conditions such that the plasmonics-active gold nanostars are produced, wherein growth of the gold nanostars is completed in about 30 seconds or less.

2. The method of claim 1 , wherein the weak reducing agent consists essentially of ascorbic acid.

3. The method of claim 1 , wherein the silver salt compound consists essentially of silver nitrate (AgNO 3 ).

4. The method of claim 1 , wherein a concentration of the HAuCl 4 ranges from about 0.2-0.3 millimolar, a concentration of the stabilized gold seeds ranges from about 20 μg/L to about 60 μg/L, and a size of the nanostar ranges from about 30 nm to about 80 nm.

5. The method of claim 1 , wherein a concentration of a silver cation of the silver compound ranges from about 5 μM to about 30 μM and a plasmon peak of the nanostar ranges from about 600 nm to about 1000 nm.

6. The method of claim 1 , wherein a plasmon peak of the nanostar ranges from about 600 nm to about 1000 nm and wherein the nanostar further comprises one or more of an optical or a non-optical label, a photosensitizer, a photoactivator, and a bioreceptor, wherein each of the optical or non-optical label, the photosensitizer, and the photoactivator absorb electromagnetic radiation emitted by the gold nanostar when the gold nanostar is excited by a single-photon or multi-photon excitation.

7. The method of claim 6 , wherein the optical label comprises one or more of a fluorescence label, a Fluorescein, a Rhodamine, a phosphorescence label, a Raman label, a 3,3′-Diethylthiadicarbocyanine iodide (DTDC) label, a photoacoustic label, an optical coherence tomography (OCT) label, and an absorbance label.

8. The method of claim 6 , wherein the non-optical label comprises one or more of a magnetic resonance imaging (MRI) label, a 1,4,7,10-Tetraazacy-clododecane-1,4,7,10-tetraacetic acid (DOTA) conjugated to a contrast agent label, a positron emission tomography (PET) label, a DOTA conjugated to a PET contrast agent label, and an ultrasound label.

9. The method of claim 6 , wherein the bioreceptor is one or more of a peptide, a cell penetrating peptide (CPP), a Human immunodeficiency virus type 1 (HIV-1) Trans-Activator of Transcription (TAT) peptide, a Multiple Antigenic Peptide (MAP), angiopep2 peptide, a cyclic Arginine-Glycine-Aspartic Acid (cRGD) peptide, transferrin, an antibody, a Human Epidermal Growth Factor Receptor 2 (HER2) antibody, a trastuzumab antibody, anti-Epidermal Growth Factor Receptor (anti-EGRF) antibody, a nucleic acid, a DNA, a cell surface receptor, and an aptamer.

10. The method of claim 6 , wherein the one or more of the optical or non-optical label, the photosensitizer, the photoactivator, and the bioreceptor are adsorbed or covalently attached to the gold nanostar or are embedded in a layer surrounding the gold nanostar.

11. The method of claim 10 , wherein the gold nanostar further comprises a drug embedded in the layer surrounding the gold nanostar such that the drug is released or activated via one or more of passive diffusion release, photochemically triggered release, thermal triggered release, pH triggered release, photochemical activation, and thermal activation.

12. The method of claim 11 , wherein the drug comprises one or more of a drug that is beneficial to a cell, a drug that is detrimental to a cell, and a small interference RNA (siRNA) designed to bind to mRNA in order to trigger or prevent gene expression.

13. The method of claim 11 , wherein the ratio of weak reducing agent to HAuCl 4 is about 1.5 to about 2.

14. The method of claim 1 , wherein the ratio of weak reducing agent to HAuCl 4 is about 1.5 to about 2.

Assignees

• Univ Duke

Inventors

• Vo-Dinh Tuan
• Yuan Hsiangkuo
• Fales Andrew

Classifications

• A61K41/0066 Primary

  Psoralene-activated UV-A photochemotherapy (PUVA-therapy), e.g. for treatment of psoriasis or eczema, extracorporeal photopheresis with psoralens or fucocoumarins · CPC title

• A61K49/0065

  the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle · CPC title

• A61K38/02 Primary

  Peptides of undefined number of amino acids; Derivatives thereof · CPC title

• A61K47/6923

  the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb · CPC title

• A61K41/0071

  PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines · CPC title